Anti-ADDL monoclonal antibody and use thereof
View Patent ↗The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
1. An isolated antibody, or antigen-binding fragment thereof, capable of differentially recognizing a multi-dimensional conformation of one or more Aβ-derived diffusible ligands, wherein said antibody comprises a complementary determining region (CDR) of Arg-Xaa 1 -Leu-Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 -Asp-Ala-Met-Asp-Tyr (SEQ ID NO:9), wherein Xaa 1 is Gln or Ala; Xaa 2 is Ser or Gly; Xaa 3 is Pro, Ala, Lys, Arg, or Thr; Xaa 4 is Lys or Arg; Xaa 5 is Gly, Ser, or Lys; Xaa 6 is Val, Thr, Ile or Arg, wherein the heavy and light chain variable regions of said antibody respectively comprise the amino acid sequence set forth in SEQ ID NO:108 and SEQ ID NO:112.
2. A kit for detecting Aβ-derived diffusible ligands comprising the isolated antibody, or antigen-binding fragment thereof, of claim 1 .
3. A method for detecting Aβ-derived diffusible ligands in a sample comprising contacting a sample with the antibody of claim 1 and determining the presence of a complex comprising the Aβ-derived diffusible ligands and the antibody.
4. An isolated antibody, or antigen-binding fragment thereof, capable of differentially recognizing a multi-dimensional conformation of one or more Aβ-derived diffusible ligands, wherein said antibody comprises a complementary determining region (CDR) of Arg-Xaa 1 -Leu-Xaa 2 -Xaa 3 -Xaa 4 -Xaa 5 -Xaa 6 -Asp-Ala-Met-A5p-Tyr (SEQ ID NO:9), wherein Xaa 1 is Gin or Ala; Xaa 2 is Ser or Gly; Xaa 3 is Pro, Ala, Lys, Arg, or Thr; Xaa 4 is Lys or Arg; Xaa 5 is Gly, Ser, or Lys; Xaa 6 is Val, Thr, Ile or Arg, wherein the heavy and light chain of said antibody respectively comprise the amino acid sequence set forth in SEQ ID NO:138 and SEQ ID NO:140.
5. A kit for detecting Aβ-derived diffusible ligands comprising the isolated antibody, or antigen-binding fragment thereof, of claim 4 .
6. A method for detecting Aβ-derived diffusible ligands in a sample comprising contacting a sample with the antibody of claim 4 and determining the presence of a complex comprising the Aβ-derived diffusible ligands and the antibody.
7. A pharmaceutical composition comprising an isolated antibody of either of claim 1 or 4 , or antigen-binding fragment thereof, capable of differentially recognizing a multi-dimensional conformation of one or more Aβ-derived diffusible ligands in admixture with a pharmaceutically acceptable carrier.
8. A method for attenuating symptoms of a disease associated with Aβ-derived diffusible ligands comprising administering an effective amount of the pharmaceutical composition of claim 7 .
9. A method for attenuating binding of Aβ-derived diffusible ligands to a neuron comprising contacting the neuron with the antibody of either of claims 1 or 4 so that binding of Aβ-derived diffusible ligands to the neuron is attenuated.
10. A method for inhibiting assembly of Aβ-derived diffusible ligands comprising contacting a sample containing amyloid β 1-42 peptides with the antibody of either of claims 1 or 4 thereby inhibiting assembly of Aβ-derived diffusible ligands.
11. A method for inhibiting the phosphorylation of tau protein at Ser202/Thr205 comprising contacting a sample containing a tau protein with the antibody of either of claims 1 or 4 thereby inhibiting the phosphorylation of tau protein at Ser202/Thr205.
12. A method for identifying a putative therapeutic agent that attenuates the binding of Aβ-derived diffusible ligands to a neuron, comprising:
a) contacting a composition comprising a neuron with Aβ-derived diffusible ligands in the presence of an agent;
b) contacting the composition with an antibody of either of claims 1 or 4 ; and
c) detecting the amount of antibody bound in the presence of the agent;
wherein a decrease in the amount of antibody bound in the presence of the agent as compared to the amount of antibody bound in the absence of the agent indicates that the agent is a putative therapeutic agent for attenuating binding of Aβ-derived diffusible ligands to neurons.